Fig. 2. VitabridC12 alleviated the Dermatophagoides farinae body (Dfb)-induced atopic dermatitis (AD)-like inflammation in the mouse model. (A) Skin lesions of AD-like skin inflammation. Images of skin lesions were taken in the 3rd week. (B) H&E stained skin recovered in the 3 weeks (×100). (C) Epidermal and dermal thickness were evaluated. VitabridC12 markedly decreased skin thickness; VitabridC12 reduced acanthosis and inflammatory cell infiltration in the AD-like skin lesions. Representative clinical presentations of the mice from the control group, Dfb group, Vitabrid group, and VitabridC12 group are shown. Data represent mean values±standard error (n=5). *p<0.05. The data shown are representative of three independent experiments.
